Author

Peter Sjö

Drugs for Neglected Diseases InitiativeORCID 0000-0002-6768-0536Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Molecular Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1

Frequent Co-Authors

A. Kenneth MacLeodiD· 1 shared Alpha A. LeeiD· 1 shared Ana Paula C. A. LimaiD· 1 shared Andrew Wells· 1 shared Annette von DelftiD· 1 shared Anthony J. WilkinsoniD· 1 shared Anthony Simon· 1 shared Benjamin PerryiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

A. Kenneth MacLeodORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Molecular BiologyPLoS PathogensPeer-reviewedMay 13, 2026

Chemical genetics reveals Leishmania KKT2 and CRK9 kinase activity is required for cell cycle progression

Juliana B. T. Carnielli, J.A. Brannigan, Nathaniel G. Jones…·Jeremy Charles Mottram

This study identifies KKT2 and CRK9 as essential kinases for Leishmania cell cycle progression using chemical genetics and CRISPR-Cas9.

6 citationstop 1%

experimental assay

𝕏 PostBluesky

Pharmacology & ToxicologybioRxivPreprintJun 16, 2025

Open-science discovery of DNDI-6510, a compound that addresses genotoxic and metabolic liabilities of the COVID Moonshot SARS-CoV-2 Mpro lead inhibitor

Ed Griffen, D. Fearon, Briana Lynn McGovern…·Annette von Delft

This paper describes the optimization of a SARS-CoV-2 Mpro inhibitor to address genotoxic and metabolic liabilities, leading to improved in vivo efficacy and exposure.

5 citations

mouseexperimental assay

𝕏 PostBluesky